首页> 外文期刊>Therapeutic Drug Monitoring >Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence
【24h】

Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence

机译:大麻依赖性药物在Dronabinol药物治疗期间的血浆大麻素浓度

获取原文
获取原文并翻译 | 示例
           

摘要

Background:Recently, high-dose oral synthetic delta-9-tetrahydrocannabinol (THC) was shown to alleviate cannabis withdrawal symptoms. The present data describe cannabinoid pharmacokinetics in chronic, daily cannabis smokers who received high-dose oral THC pharmacotherapy and later a smoked cannabis challenge.Methods:Eleven daily cannabis smokers received 0, 30, 60, or 120 mg/d THC for four 5-day medication sessions, each separated by 9 days of ad libitum cannabis smoking. On the fifth day, participants were challenged with smoking one 5.9% THC cigarette. Plasma collected on the first and fifth days was quantified by two-dimensional gas chromatography mass spectrometer for THC, 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Linear ranges (ng/mL) were 0.5-100 for THC, 1-50 for 11-OH-THC, and 0.5-200 for THCCOOH.Results:During placebo dosing, THC, 11-OH-THC, and THCCOOH concentrations consistently decreased, whereas all cannabinoids increased dose dependently during active dronabinol administration. THC increase over time was not significant after any dose, 11-OH-THC increased significantly during the 60- and 120-mg/d doses, and THCCOOH increased significantly only during the 120-mg/d dose. THC, 11-OH-THC, and THCCOOH concentrations peaked within 0.25 hours after cannabis smoking, except after 120 mg/d THC when THCCOOH peaked 0.5 hours before smoking.Conclusions:The significant withdrawal effects noted during placebo dronabinol administration were supported by significant plasma THC and 11-OH-THC concentration decreases. During active dronabinol dosing, significant dose-dependent increases in THC and 11-OH-THC concentrations support withdrawal symptom suppression. THC concentrations after cannabis smoking were only distinguishable from oral THC doses for 1 hour, too short a period to feasibly identify cannabis relapse. THCCOOH/THC ratios were higher 14 hours after overnight oral dronabinol abstinence but cannot distinguish oral THC dosing from the smoked cannabis intake.
机译:背景:最近,高剂量口服合成的delta-9-四氢大麻酚(THC)被证明可以缓解大麻戒断症状。当前数据描述了接受大剂量口服THC药物治疗并随后抽烟的大麻挑战的慢性,日常大麻吸烟者的大麻素药代动力学方法:11名每日大麻吸烟者接受4、5、5、30、60或120 mg / d THC每天服药,每次间隔9天随意抽大麻。在第五天,参加者被挑战吸烟一根5.9%THC烟。在第一天和第五天收集的血浆通过二维气相色谱质谱仪对THC,11-羟基-THC(11-OH-THC)和11-nor-9-羧基-THC(THCCOOH)进行定量。 THC的线性范围(ng / mL)为0.5-100,11-OH-THC的线性范围为1-50,THCCOOH的线性范围为0.5-200。结果:安慰剂给药期间,THC,11-OH-THC和THCCOOH浓度持续降低,而在活性屈大麻酚给药期间,所有大麻素剂量依赖性增加。在任何剂量下,THC随时间的增加均不显着,在60和120 mg / d剂量下11-OH-THC显着增加,仅在120 mg / d剂量下THCCOOH显着增加。大麻吸烟后,THC,11-OH-THC和THCCOOH的浓度在0.25小时内达到峰值,但在吸烟前0.5小时THCCOOH达到峰值的120 mg / d THC之后,THC,11-OH-THC和THCCOOH的浓度除外。 THC和11-OH-THC浓度降低。在积极的屈大麻酚剂量期间,THC和11-OH-THC浓度的显着剂量依赖性增加可支持戒断症状抑制。大麻吸烟后1小时内的THC浓度仅与口服THC剂量区分开,时间太短以致无法确定大麻的复发。隔夜口服Dronabinol戒断14小时后,THCCOOH / THC比率较高,但无法区分口服THC剂量与烟熏大麻摄入量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号